Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35650449)
Watch
English
Platinum-based chemotherapy in metastatic breast cancer: current status.
scientific article published on February 2004
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
review article
1 reference
stated in
Europe PubMed Central
title
Platinum-based chemotherapy in metastatic breast cancer: current status
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
main subject
chemotherapy
1 reference
based on heuristic
inferred from title
platinum
1 reference
based on heuristic
inferred from title
metastatic breast cancer
1 reference
based on heuristic
inferred from title
author
Santhanam Sundar
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
author name string
Decatris MP
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
O'Byrne KJ
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
publication date
1 February 2004
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
published in
Cancer Treatment Reviews
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
volume
30
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
page(s)
53-81
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
issue
1
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
cites work
Treatment of breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy for metastatic breast cancer-report of a European expert panel
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The platinum agents: a role in breast cancer treatment?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interactions between mammalian cell DNA and inorganic platinum compounds. II. Interstrand cross-linking of isolated and cellular DNA by platinum(IV) compounds.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optimum management of nausea and vomiting in cancer chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Controlling emesis related to cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-Dose Cisplatin in Hypertonic Saline
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin neurotoxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I studies with carboplatin at the Royal Marsden Hospital
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I study of oxaliplatin in patients with advanced cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Platinum compounds in the treatment of advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin and its analogues in the treatment of advanced breast cancer: a review
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin as first-line therapy for metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of escalating doses of cisplatin in hypertonic saline
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of dose on the bioavailability of oral etoposide.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The clinical pharmacology of etoposide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
[Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer]
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Etoposide in the management of metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study with etoposide in previously untreated advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin and VP16 in metastatic breast carcinoma as a third-line chemotherapy: a randomized study comparing low versus high doses of cisplatin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Single and combination nonhormonal chemotherapy in breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mitomycin C in large infrequent doses in breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mitomycin C: a review
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin and mitomycin C in advanced chemotherapy-refractory breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Paclitaxel (taxol)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Taxol and cisplatin inhibit proliferation of T47D human breast cancer cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New cytotoxic agents and schedules for advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Docetaxel
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vinorelbine (Navelbine): a third-generation vinca alkaloid
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Advanced breast cancer: a phase II trial with gemcitabine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine and targeted therapy in metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine plus cisplatin for the treatment of metastatic breast cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Actual 5-year survival of patients with stage IIIB breast carcinoma: phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical Studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of carboplatin and etoposide in metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin in combination as first-line therapy in advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HER-2/neu as a predictive marker of response to breast cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line Herceptin monotherapy in metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Induction Chemotherapy with Cisplatin, Doxorubicin, and Cyclophosphamide (CAP) in a Combined Modality Approach for Locally Advanced and Inflammatory Breast Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of 4-epirubicin, etoposide and cisplatin as neoadjuvant chemotherapy in locally advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin and Etoposide in Chemotherapy-Refractory Advanced Breast Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclophosphamide, Adriamycin, and cis-Platinum (CAP) in Metastatic and Locally Advanced Breast Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy with cis-Platin, Doxorubicin, and Cyclophosphamide (CAP) in Patients with Metastatic Breast Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inefficiency of cisplatin plus 5-FU as second-or third line treatment in advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin: an active drug in metastatic breast cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin activity in untreated metastatic breast cancer patients--results of a phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracyclines.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of carboplatin and etoposide activity in pretreated breast cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of carboplatin and VP-16 for patients with metastatic breast cancer and only one prior chemotherapy regimen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Negative phase II study with carboplatin and 5-fluorouracil in advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of standard-dose carboplatin, cyclophosphamide, and etoposide in patients with metastatic breast cancer with previous exposure to anthracyclines
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900139-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0305-7372(03)00139-7
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
PubMed ID
14766126
1 reference
stated in
Europe PubMed Central
PubMed ID
14766126
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766126%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
